FGFR inhibitors for the treatment of cancer
US12409177B2 · kind B2 · utility
0Cited by
3References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2020 |
| Grant date | Sep 9, 2025 |
| Priority date | — |
| Expiry date | Sep 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.